U.S. markets open in 4 hours 13 minutes
  • S&P Futures

    3,422.00
    -10.50 (-0.31%)
     
  • Dow Futures

    28,043.00
    -91.00 (-0.32%)
     
  • Nasdaq Futures

    11,652.50
    -38.75 (-0.33%)
     
  • Russell 2000 Futures

    1,601.80
    -1.30 (-0.08%)
     
  • Crude Oil

    40.20
    +0.17 (+0.42%)
     
  • Gold

    1,919.30
    -10.20 (-0.53%)
     
  • Silver

    24.94
    -0.30 (-1.19%)
     
  • EUR/USD

    1.1844
    -0.0022 (-0.19%)
     
  • 10-Yr Bond

    0.8160
    0.0000 (0.00%)
     
  • Vix

    29.32
    -0.03 (-0.10%)
     
  • GBP/USD

    1.3097
    -0.0046 (-0.35%)
     
  • USD/JPY

    104.7200
    +0.1600 (+0.15%)
     
  • BTC-USD

    12,795.70
    +1,738.69 (+15.72%)
     
  • CMC Crypto 200

    256.74
    +11.85 (+4.84%)
     
  • FTSE 100

    5,759.18
    -17.32 (-0.30%)
     
  • Nikkei 225

    23,474.27
    -165.19 (-0.70%)
     

Biofrontera to Participate in Upcoming Investor Conferences

Leverkusen, Germany, Nov. 22, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the "Company"), an international biopharmaceutical company, today announced its participation at the following events:

Event: Deutsches Eigenkapitalforum / Analyst conference
Format: Presentation & 1x1 Meetings
Date: Monday, November 25, 2019
Time: 5:00pm CET
Location: Sheraton Frankfurt Airport Hotel & Conference Center, Frankfurt/Main, Germany

Event: Benchmark Discovery 1x1 Conference
Format: 1x1 Meetings
Date: Wednesday, December 4, 2019
Location: The New York Athletic Club, New York, NY

Event: 12th Annual LD Micro Main Event
Format: Presentation & 1x1 Meetings
Date: Wednesday, December 11, 2019
Time: 10:00am PT
Location: Luxe Sunset Boulevard Hotel, Los Angeles, CA: Track 2

-End-

Enquiries, please contact:

Biofrontera AG

Thomas Schaffer, Chief Financial Officer



+49 (0) 214 87 63 2 0

ir@biofrontera.com

IR UK: Seton Services

Toni Vallen

+44(0) 20 7729 0805

IR and PR US: The Ruth Group

IR: Tram Bui

PR: Kirsten Thomas



+1 646-536-7035

+1 508-280-6592

About Biofrontera:

Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics.

The Germany-based company, with almost 200 employees worldwide, develops and markets innovative products for the care, protection and treatment of the skin. The company’s lead product is the combination of Ameluz®, a topical prescription drug, and medical device BF-RhodoLED® for the photodynamic therapy of certain superficial skin cancers and their precursors. Ameluz® has been marketed in the EU since 2012 and in the United States since May 2016. In addition, the company markets the prescription medication Xepi for the treatment of impetigo in the United States. In the EU, the company also sells the dermocosmetics series Belixos®, which offers specialized care for damaged or diseased skin.

Biofrontera is the first German founder-led pharmaceutical company to receive a centralized European and a US approval for a drug developed in-house. The Biofrontera Group was founded in 1997 by the current CEO Prof. Dr. Hermann Lübbert and is listed on the Frankfurt Stock Exchange (Prime Standard) and on the US NASDAQ. www.biofrontera.com.